Reduction of Combined Modality Treatment Intensity in Early Stage Hodgkin’s Lymphoma: Interim Analysis of the HD 10 Trial of the GHSG.

Diehl, V; Brillant, C; Engert, A; Wolf, J; Nogova, L; Mueller, RP; Eich, H; Mueller-Hermelink, HK; Herrmann, R; Doerken, B; Kanz, L; Greil, R; Pfistner, B; Blood. 2004; 104(11):1307–46th Annual Meeting of American Society of Hematology (ASH); 04.-07.12.2004; San Diego, California.

Pegfilgrastim Supports Delivery of CHOP-R Chemotherapy Administered Every 14 Days: A Randomised Phase II Study._x000D_

Lopez, A; de Sevilla, AF; Castaigne, S; Greil, R; Sierra, J; Sanchez, J; Easton, V; Bacon, P; ashmtg, 11_x000D_ . 2004. 104: 3311-3311.

Elevated levels of soluble CD44 are associated with advanced disease and in vitro proliferation of neoplastic lymphocytes in B-cell chronic lymphocytic leukaemia.

Eisterer, W; Bechter, O; Söderberg, O; Nilsson, K; Terol, M; Greil, R; Thaler, J; Herold, M; Finke, L; Günthert, U; Montserrat, E; Stauder, R; LEUKEMIA RES. 2004; 28(10): 1043-1051.

Gemcitabine combined with epirubicin in the treatment of patients with locally advanced or metastatic breast cancer: a phase II study.

Hausmaninger, H; Morack, G; Heinrich, B; Wallwiener, D; Höffken, K; Buksmaui, S; Krejcy, K; Miller, MA; Possinger, K; AM J CLIN ONCOL-CANC. 2004; 27(4): 429-435.

Is higher income and educational status associated with poorer outcome in patients with Hodgkin“s disease?

Holzner, B; Fischhofer, M; Kemmler, G; Kopp, M; Sperner-Unterweger, B; Krugmann, J; Dirnhofer, S; Greil, R; EUR J HAEMATOL. 2004; 73(5): 318-324.

Quality of life of patients with chronic lymphocytic leukemia: results of a longitudinal investigation over 1 yr.

Holzner, B; Kemmler, G; Kopp, M; Nguyen-Van-Tam, D; Sperner-Unterweger, B; Greil, R; Eur J Haematol. 2004; 72(6):381-389

Treatment of advanced Hodgkinxxxs disease with COPP/ABV/IMEP versus COPP/ABVD and consolidating radiotherapy: final results of the German Hodgkinxxxs Lymphoma Study Group HD6 trial

Sieber, M; Tesch, H; Pfistner, B; Rueffer, U; Paulus, U; Munker, R; Hermann, R; Doelken, G; Koch, P; Oertel, J; Roller, S; Worst, P; Bischof, H; Glunz, A; Greil, R; von Kalle, K; Schalk, KP; Hasenclever, D; Brosteanu, O; Duehmke, E; Georgii, A; Engert, A; Loeffler, M; Diehl, V ANN ONCOL. 2004; 15(2): 276-282.

Normative data for functional assessment of cancer therapy–general scale and its use for the interpretation of quality of life scores in cancer survivors.

Holzner, B; Kemmler, G; Cella, D; De Paoli, C; Meraner, V; Kopp, M; Greil, R; Fleischhacker, WW; Sperner-Unterweger, B; Acta Oncol. 2004; 43(2):153-160

Unfavourable prognosis of patients with trisomy 18q21 detected by fluorescence in situ hybridisation in t(11;18) negative, surgically resected, gastrointestinal B cell lymphomas.

Krugmann, J; Tzankov, A; Dirnhofer, S; Fend, F; Greil, R; Siebert, R; Erdel, M; J CLIN PATHOL. 2004; 57(4): 360-364.

Phase II study of single-agent pegylated liposomal doxorubicin HCl (PLD) in metastatic breast cancer after first-line treatment failure.

Mlineritsch, B; Mayer, P; Rass, C; Reiter, E; Russ, G; Vesenmayer, G; Oberaigner, W; Hausmaninger, H; Onkologie. 2004; 27(5): 441-446.